CASI Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-3.021; its P/E ratio is -0.83; CASI Pharmaceuticals is scheduled to report earnings on May 20, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Sep 22	Jun 22	Mar 22
Income Statement	-
Total Revenue	-	$ 15.26M	$ 10.21M	$ 8.57M	$ 9.06M
Gross Profit	-	$ 10.99M	$ 5.97M	$ 5.02M	$ 5.30M
EBIT	-	$ -16.52M	$ -5.02M	$ -7.75M	$ -7.29M
EBITDA	-	$ -15.63M	$ -4.26M	$ -7.41M	$ -6.86M
Net Income Common Stockholders	-	$ -19.54M	$ -5.20M	$ -7.68M	$ -8.60M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 30.77M	$ 49.88M	$ 35.55M	$ 24.57M	$ 37.48M
Total Assets	$ 75.27M	$ 96.23M	$ 127.91M	$ 118.86M	$ 129.56M
Total Debt	$ 18.89M	$ 0.00	$ 3.00M	$ 2.90M	$ 1.88M
Net Debt	$ -11.87M	$ -49.88M	$ -32.55M	$ -21.67M	$ -35.60M
Total Liabilities	$ 51.10M	$ 29.30M	$ 44.69M	$ 29.25M	$ 54.58M
Stockholders Equity	$ 24.16M	$ 44.53M	$ 61.71M	$ 66.94M	$ 74.99M
Cash Flow	-
Free Cash Flow	-	$ -4.27M	$ -6.99M	$ -8.91M	$ -6.53M
Operating Cash Flow	-	-	$ -6.52M	$ -9.48M	$ -4.24M
Investing Cash Flow	-	-	$ 16.45M	$ -961.00K	$ -2.29M
Financing Cash Flow	-	-	$ 2.00M	$ 1.00M	$ -3.00M

Currency in USD

CASI Pharmaceuticals Earnings and Revenue History

Income Statement >

CASI Pharmaceuticals Debt to Assets

Balance Sheet >

CASI Pharmaceuticals Cash Flow

Cash Flow >

CASI Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing